Prognostic Relevance of ctDNA RAS Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab
Clinical Colorectal Cancer · 2025
DOI: 10.1016/j.clcc.2025.03.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2025. Verfasst von Seong-Eun Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Cetuximab, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Circulating Tumor DNA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Merck KGaA, Korean Foundation for Cancer Research.
Abstract (Originalsprache)
BACKGROUND: RAS mutations are important biomarkers for predicting the efficacy of anti-EGFR treatment in metastatic colorectal cancer (mCRC). The emergence of RAS mutations is a known resistance mechanism. This study aimed to evaluate the prognostic significance of circulating tumor DNA (ctDNA) RAS mutations in patients with mCRC treated with cetuximab, focusing on the temporal dynamics of RAS mutation emergence. PATIENTS AND METHODS: Patients with tissue-confirmed RAS wild-type mCRC were included in the study. ctDNA samples were collected at baseline, every 8 weeks during treatment, and after the final cetuximab dose. Cetuximab, combined with FOLFOX or FOLFIRI, was administered as first-line therapy. The primary objective was to assess the impact of emergent ctDNA RAS mutations on progression-free survival (PFS) during cetuximab-based treatment in the first-line setting. RESULTS: A total of 49 patients contributed at least 1 ctDNA sample, with 320 samples collected in total. The baseline concordance rate between ctDNA and tissue RAS status was 89.1% (41/46). Among 41 baseline RAS wild-type cases, 22 (53.7%) demonstrated emergent RAS mutations. The median time to RAS emergence was 12.8 months, and the median PFS was 12.7 months. Temporal analysis revealed that a single detection of RAS mutation was not consistently associated with poor PFS and could resolve in subsequent tests. However, time-dependent analysis indicated that the presence of ctDNA RAS mutations at any time point was significantly associated with poorer PFS (adjusted HR = 2.24, P = .02). CONCLUSION: The emergence of ctDNA RAS mutations during cetuximab-based first-line therapy exhibits temporal variability. Nevertheless, the presence of ctDNA RAS mutations at any time point is collectively associated with reduced PFS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address: sunyoungkim@amc.seoul.kr.
Förderung
- Merck KGaA
- Korean Foundation for Cancer Research
Zitieren
APA
Kim, S. E., Lee, J. S., Kim, S. Y., Kim, J. E., Hong, Y. S., & Kim, T. W. (2025). Prognostic Relevance of ctDNA RAS Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2025.03.002
Vancouver
Kim SE, Lee JS, Kim SY, Kim JE, Hong YS, Kim TW. Prognostic Relevance of ctDNA RAS Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab. Clinical Colorectal Cancer. 2025. doi:10.1016/j.clcc.2025.03.002
BibTeX
@article{Kim2025,
author = {Kim, Seong-Eun and Lee, Ji Sung and Kim, Sun Young and Kim, Jeong Eun and Hong, Yong Sang and Kim, Tae Won},
title = {Prognostic Relevance of ctDNA RAS Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab},
journal = {Clinical Colorectal Cancer},
year = {2025},
doi = {10.1016/j.clcc.2025.03.002}
}
EUVIMED